Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Orthopaedic Surgery
  •  Pediatric Surgery
  •  Neurological Surgery
  •  Breast Surgery
  •  Gastroenterological Surgery
  •  Otolaryngology - Head and Neck Surgery
  •  Cardiovascular Surgery
  •  Thoracic Surgery


Citation: Clin Surg. 2022;7(1):3596.Research Article | Open Access

Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©

Jansen C#, Wagner RM#, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, Lehmann J, Strassburg CP and Trebicka J

Department of Internal Medicine I, University of Bonn, Germany
Medical Department B, University Clinic Münster, Germany
European Foundation for Study of Chronic Liver Failure, Spain
#Both authors contributed equally to this work

*Correspondance to: Christian Jansen 

 PDF  Full Text DOI: 10.25107/2474-1647.3596


Background: Ascites is the common cause of decompensation in patients with cirrhosis. It has been ascertained that 5% to 10% of patients with end stage liver disease showed in case of compensation the develop of ascites every year. The alfapump© reduces the need for large volume paracentesis and can improve life quality. The aim of our study was to assess the role of the use of Non-Selective Beta-Blocker (NSBB) characteristics and outcomes of patients with cirrhosis receiving alfapump© and to find predictors of a longer life in a palliative concept. Methods: Seventeen (13 males) patients with liver cirrhosis receiving an alfapump© were included in this case-series. Clinical parameters were assessed before the insertion of the alfapump© and during follow-up. As part of the follow-up, all patients received the standard of care as recommended by European Association for the Study of the Liver and DGVS. Results: Could generally be identified as the cause of death. If the patients were stratified according to the use of a non-selective beta-blocker, we can see that the group taking non-selective beta blocker had a longer survival. These data to verify previous finding that NSBB in this very high-risk patient may delay infections and improve outcome. Conclusion: This study suggests a protective effect of NSBB in patients after implantation of an alfapump©. Although confirmation is needed, this may help management of patients receiving the device.


Liver; Cirrhosis; Ascites; Alfapump©; Non-selective beta blocker

Cite the article

Jansen C, Wagner RM, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, et al. Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©. Clin Surg. 2022; 7: 3596..

Search Our Journal

Journal Indexed In

Articles in PubMed

Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 PubMed  PMC  PDF  Full Text
Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Long Noncoding RNA LINC00520 Accelerates the Progression of Colorectal Cancer by Serving as a Competing Endogenous RNA of Microrna-577 to Increase HSP27 Expression
 Abstract  PDF  Full Text
The Effect of Foot Reflexology on the Time of Full Consciousness Recovery and Weaning from Mechanical Ventilation in Patients with Brain Tumor after Craniotomy
 Abstract  PDF  Full Text
View More...